A Phase 2/3 Randomized Double-Blind Multicenter Multinational 4-Arm Controlled Dose-Ranging Study to Evaluate Efficacy and Safety of Telizumab (MGA031) FcR Non-Binding Anti-CD3 Monoclonal Antibody in Children and Adults with recent-Onset Type 1
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
No Description Available
Description
No Description Available
Details
| Age | 18years - 35years |
|---|---|
| Clinical Study Identifier | TX1963 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.